Utidelone

Utidelone
Clinical data
Trade names	優替帝
Other names	Epothilone D; desoxyepothilone B
ATC code	L01DC05 (WHO) ;
Legal status
Legal status	Rx in China;
Identifiers
CAS Number	189453-10-9;
PubChem CID	447865;
DrugBank	DB17575;
UNII	T0358E0YUF;
CompTox Dashboard (EPA)	DTXSID70880053 ;
Chemical and physical data
Formula	C27H41NO5S
Molar mass	491.69 g·mol−1

Utidelone is a pharmaceutical drug for the treatment of metastatic breast cancer. It was approved for use in China in 2021.^[1]^[2]

Utidelone is a member of the epothilone class of natural products, which are metabolites produced by the soil-dwelling myxobacterium Sorangium cellulosum.^[3] It is also known as epothilone D.

References

^ "New Drug Approvals in China in 2021". diaglobal.org. 2 May 2022.
^ Villegas C, González-Chavarría I, Burgos V, Iturra-Beiza H, Ulrich H, Paz C (March 2023). "Epothilones as Natural Compounds for Novel Anticancer Drugs Development". International Journal of Molecular Sciences. 24 (7): 6063. doi:10.3390/ijms24076063. PMC 10093981. PMID 37047035.
^ Avendaño C, Menéndez JC (2023). "Anticancer drugs targeting tubulin and microtubules". Medicinal Chemistry of Anticancer Drugs: 445–491. doi:10.1016/B978-0-12-818549-0.00017-0. ISBN 978-0-12-818549-0.